To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures

To evaluate the long-term safety and efficacy of pregabalin in patients with partial seizures.

Completed

Looking for future studies?

Key information

Conditions

Seizure Disorder, Partial Brain Diseases Central Nervous System Diseases Epilepsies, Partial Epilepsy Nervous System Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Pfizer Investigational Site, Edmont, Alberta, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Must have met the inclusion criteria for the preceding double-blind study
Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion criteria

Cannot have absence seizures.

Treatment and study plan

Pregabalin

Drug

Primary outcomes

Safety Efficacy

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

Pregabalin Open-Label Add-On Trial: An Open-Label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.

Important dates

Study start: 1998
Study completion: 2005
First posted: Sep 1, 2005
Registry last updated: Nov 6, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed